Streetbeat News

Analyst Ratings

ECC

B. Riley Securities analyst Matt Howlett maintains a Buy rating on Eagle Point Credit Co (NYSE:ECC) and lowers the price target from $13 to $12.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 12:43 pm

OXLC

B. Riley Securities analyst Matt Howlett maintains a Buy rating on Oxford Lane Capital (NASDAQ:OXLC) but lowers the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 12:42 pm

NVRO

Canaccord Genuity analyst William Plovanic maintains a Buy rating on Nevro (NYSE:NVRO) but lowers the price target from $76 to $68.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 12:42 pm

EPAM

Citigroup analyst Ashwin Shirvaikar downgraded EPAM Sys (NYSE:EPAM) from Buy to Neutral and lowered the price target from $310 to $220.

Portfolio Pulse from richadhand@benzinga.com

June 06, 2023 | 12:41 pm

MDB

Canaccord Genuity analyst David Hynes maintains a Buy rating on MongoDB (NASDAQ:MDB) and raises the price target from $250 to $410.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 12:40 pm

ESTC

Canaccord Genuity analyst Kingsley Crane maintains a Buy rating on Elastic (NYSE:ESTC) and raises the price target from $70 to $79.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 12:39 pm

CSTL

Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $60 to $40.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 12:39 pm

RARE

Evercore ISI Group analyst Liisa Bayko has upgraded Ultragenyx Pharmaceutical (NASDAQ:RARE) from In-Line to Outperform and raised the price target from $60 to $80.

Portfolio Pulse from richadhand@benzinga.com

June 06, 2023 | 12:38 pm

OSCR

B of A Securities analyst Kevin Fischbeck upgrades Oscar Health (NYSE:OSCR) from Underperform to Neutral and raises the price target from $5.4 to $8.75.

Portfolio Pulse from richadhand@benzinga.com

June 06, 2023 | 12:37 pm

HOTH

MREO

ZURA

Hoth Therapeutics announces positive preclinical results for HT-ALZ Alzheimer's treatment, Zura Bio completes $80 million financing to advance ZB-106, and Needham reiterates buy on Mereo BioPharma with a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 12:37 pm